Loop Capital Has Lowered Expectations for Tempus AI (NASDAQ:TEM) Stock Price

Tempus AI (NASDAQ:TEM - Free Report) had its target price cut by Loop Capital from $57.00 to $52.00 in a research report report published on Tuesday,Benzinga reports. They currently have a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Stifel Nicolaus cut Tempus AI from a "buy" rating to a "hold" rating and lifted their price target for the company from $45.00 to $65.00 in a research report on Monday, November 11th. Wolfe Research assumed coverage on shares of Tempus AI in a report on Friday, December 13th. They issued an "outperform" rating and a $60.00 target price on the stock. Guggenheim initiated coverage on shares of Tempus AI in a research report on Monday, December 9th. They issued a "buy" rating and a $74.00 price target on the stock. Bank of America increased their price objective on Tempus AI from $52.00 to $54.00 and gave the company a "neutral" rating in a research report on Friday, December 13th. Finally, Piper Sandler reaffirmed a "neutral" rating and set a $70.00 target price (up from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Three equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Tempus AI currently has an average rating of "Moderate Buy" and an average price target of $56.36.

Tempus AI Stock Down 1.6 %

TEM traded down $0.51 during trading hours on Tuesday, hitting $31.83. The company's stock had a trading volume of 4,016,626 shares, compared to its average volume of 4,069,895. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The company has a 50-day simple moving average of $47.94 and a 200 day simple moving average of $47.28.

Insider Buying and Selling

In related news, EVP Andrew Polovin sold 51,504 shares of the business's stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.39, for a total value of $2,183,254.56. Following the completion of the sale, the executive vice president now directly owns 246,085 shares in the company, valued at approximately $10,431,543.15. The trade was a 17.31 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director David R. Epstein sold 620 shares of the business's stock in a transaction on Wednesday, December 11th. The stock was sold at an average price of $41.81, for a total transaction of $25,922.20. Following the completion of the sale, the director now owns 27,894 shares of the company's stock, valued at $1,166,248.14. The trade was a 2.17 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 865,041 shares of company stock worth $35,917,673.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of the company. Kovitz Investment Group Partners LLC bought a new position in Tempus AI during the third quarter valued at about $1,367,000. Sumitomo Mitsui Trust Group Inc. boosted its stake in Tempus AI by 1,591.2% during the third quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company's stock worth $68,922,000 after buying an additional 1,145,698 shares in the last quarter. Captrust Financial Advisors acquired a new stake in Tempus AI during the third quarter worth $2,726,000. Dakota Wealth Management bought a new stake in Tempus AI in the 3rd quarter valued at $1,185,000. Finally, Sigma Planning Corp acquired a new position in shares of Tempus AI in the 3rd quarter valued at $1,323,000. Institutional investors own 24.22% of the company's stock.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.